BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J;  FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67:918-924. [PMID: 28736139 DOI: 10.1016/j.jhep.2017.07.012] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 23.6] [Reference Citation Analysis]
2 Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26:936-941. [PMID: 30803099 DOI: 10.1111/jvh.13091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
5 Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, Zhu R, Gao Z. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014;59:50-4. [DOI: 10.1016/j.jcv.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizábal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014;21:590-6. [DOI: 10.1111/jvh.12200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
7 Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol 2015;30:918-24. [PMID: 25532588 DOI: 10.1111/jgh.12874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
8 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatol Commun 2020;4:8-20. [PMID: 31909352 DOI: 10.1002/hep4.1436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
10 Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8:e68568. [PMID: 23844222 DOI: 10.1371/journal.pone.0068568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
11 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
12 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
13 Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017;37 Suppl 1:52-58. [PMID: 28052620 DOI: 10.1111/liv.13314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
14 Wooddell CI, Gehring AJ, Yuen MF, Given BD. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses 2021;13:581. [PMID: 33808298 DOI: 10.3390/v13040581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pérez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int. 2014;34 Suppl 1:146-153. [PMID: 24373092 DOI: 10.1111/liv.12398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
16 van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
17 Lu J, Li J, Liu Y, Ren S, Cao Z, Jin Y, Ma L, Shen C, Chen X. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS One 2015;10:e0141072. [PMID: 26524467 DOI: 10.1371/journal.pone.0141072] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kang K, Kim JH. [Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?]. Korean J Gastroenterol 2014;63:329-32. [PMID: 25007428 DOI: 10.4166/kjg.2014.63.5.329] [Reference Citation Analysis]
20 Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. Korean J Gastroenterol. 2016;67:28-34. [PMID: 26809629 DOI: 10.4166/kjg.2016.67.1.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Xu WX, Zhang Q, Zhu X, Lin CS, Chen YM, Deng H, Mei YY, Zhao ZX, Xie DY, Gao ZL, Xie C, Peng L. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Can J Gastroenterol Hepatol 2018;2018:1817680. [PMID: 29862225 DOI: 10.1155/2018/1817680] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
22 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
23 Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016;63:1481-92. [PMID: 27100145 DOI: 10.1002/hep.28438] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 22.2] [Reference Citation Analysis]
24 Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol 2016;16:38. [PMID: 26987437 DOI: 10.1186/s12876-016-0454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
25 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
26 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
27 Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016;43:43-8. [PMID: 26523639 DOI: 10.1016/j.ijid.2015.10.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
28 Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. Am J Gastroenterol. 2016;111:1286-1294. [PMID: 27045923 DOI: 10.1038/ajg.2016.109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]